RxDoctor Payments Data

Judy Rawls, MD

Family Medicine · Madison, ALNPI 1598748931

Payments from drug & device makers

$12,033in general payments, 2019–2025

Across 864 payments — averaging $13.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$854
  • Amgen$564
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$12,022100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,033 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$201,104
Medicare patients
447
Services billed
3,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$42,500
RybelsusSemaglutide20$33,330
FarxigaDapagliflozin Propanediol27$30,087
XareltoRivaroxaban34$25,561
Xigduo XrDapaglifloz Propaned/Metformin28$20,131
JardianceEmpagliflozin15$17,648
EliquisApixaban19$15,827
MounjaroTirzepatide13$14,863
Synjardy XrEmpagliflozin/Metformin Hcl15$13,403
Soliqua 100-33Insulin Glargine/Lixisenatide12$13,393
Repatha SureclickEvolocumab15$11,806
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$10,614
BelsomraSuvorexant11$9,795
DayvigoLemborexant15$7,294
PremarinEstrogens, Conjugated21$4,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,350$75,83044 claims
Boehringer IngelheimJardiance, Synjardy Xr$109$31,05130 claims
AstraZenecaFarxiga$1,298$30,08727 claims
Johnson & JohnsonXarelto$54$25,56134 claims
PfizerEliquis, Premarin$854$20,75840 claims
Lilly USA, LLCMounjaro$1,184$14,86313 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$395$13,39312 claims
MerckBelsomra$129$9,79511 claims
Eisai Inc.Dayvigo$240$7,29415 claims
AbbVieSynthroid$1,780$1,75243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →